Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Current Opinion in Investigational Drugs (London, England : 2000)|October 31, 2009
PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategiesStephanie J Harris, John G Foster, Stephen G WardFuture Oncology (London, England)|December 23, 2014
The hypoxic tumor microenvironment: driving the tumorigenesis of non-small-cell lung cancerJohn G Foster, Sybil C K Wong, Tyson V SharpPharmacological Reviews|October 2, 2012
Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignanciesJohn G Foster, Matthew D Blunt, Edward Carter, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 16, 2013
Mitochondrial superoxide generation enhances P2X7R-mediated loss of cell surface CD62L on naive human CD4+ T lymphocytesJohn G Foster, Edward Carter, Iain Kilty, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 16, 2011
Evidence that the lipid phosphatase SHIP-1 regulates T lymphocyte morphology and motilityStephanie J Harris, Richard V Parry, John G Foster, et al.Cell Reports|September 28, 2022
FOXA1 regulates alternative splicing in prostate cancerMarco Del Giudice, John G Foster, Serena Peirone, et al.Cell Reports|July 7, 2017
Argonaute Utilization for miRNA Silencing Is Determined by Phosphorylation-Dependent Recruitment of LIM-Domain-Containing ProteinsKatherine S Bridge, Kunal M Shah, Yigen Li, et al.EMBO Molecular Medicine|June 23, 2018
A HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxiaDaniel E Foxler, Katherine S Bridge, John G Foster, et al.Pageof 1